Marc Moodley has worked at Sanofi since 2018 and is the new medical ... How do you think NICE should change its reviews of oncology products? The NHS and the government have taken a positive ...

Revolution Medicines Inc's commitment to precision oncology positions it at the forefront ... such as the prior agreement ...

“Tecentriq, in combination with Avastin, is the only cancer immunotherapy treatment, approved by NICE for this indication,” said Gemma Boni, head of liver cancer at Roche Products Ltd. “We ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage its PRO-XTEN platform for T-cell engagers. The strategic shift includes ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

Sanofi is now in “exclusive negotiations ... Some of its most popular products include the antihistamine Allegra, non-opioid pain reliever Doliprane, stomach cramp reliever Buscopan, Selsun ...

Shares were up 3.4% in pre-market trading on Monday morning but are down nearly 41% year-to-date. The French government has taken a small stake in Sanofi's consumer healthcare business Opella, ...